⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10427592 | 0.80 | — | — | |
| SCHEMBL21518545 | 0.80 | — | — | |
| SCHEMBL5470071 | 0.75 | RNPEP (0.38) | — | |
| SCHEMBL7950805 | 0.75 | — | — | |
| SCHEMBL5867412 | 0.75 | TDP1 (0.37) | — | |
| SCHEMBL5469952 | 0.75 | RNPEP (0.39) | — | |
| SCHEMBL8556461 | 0.73 | — | — | |
| SCHEMBL564157 | 0.71 | — | — | |
| SCHEMBL5456827 | 0.71 | RNPEP (0.46) | — | |
| SCHEMBL3069492 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109310781-B | Specific antibody-drug-conjugates (ADC) having a KSP inhibitor and an anti-CD 123-antibody | 拜耳制药股份公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | US | disclosed |
| US-20230399411-A1 | SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-12-14 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11643469-B2 | Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-05-09 | — | — | US | disclosed |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| EP-3471776-B1 | SPECIFIC ANTIBODY-DRUG-CONJUGATES WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES | Bayer Pharma AG (DE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3919518-A1 | SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2021-12-08 | — | — | EP | disclosed |
| CN-107635586-B | Antibody-drug conjugates (ADC) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies | 拜耳医药股份有限公司 | 2021-09-24 | — | — | CN | disclosed |
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-09-21 | — | — | US | disclosed |
| US-20180318438-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | US | disclosed |
| US-20180318437-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | US | disclosed |
| US-10022453-B2 | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma AG (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
| WO-2017216028-A1 | SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-21 | — | — | WO | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
| EP-0094052-A2 | 1-(1,3-Dioxolan-2-yl-methyl)-1H-imidazoles and -1H-1,2,4-triazoles and their salts, process for their preparation, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-11-16 | — | — | EP | disclosed |
| US-4105763-A | 1-Methyl-2-(phenyl-oxymethyl)-5-nitro-imidazoles | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-08-08 | — | — | US | disclosed |